Exosome-based treatments hold promise, but their reality has not yet materialized in the form of compelling clinical data. Belgian biotech Exo Biologics’ CEO Hugues Wallemacq believes his company can help move the field forward, both through its own clinical programs and by offering high-quality exosomes to others in the field. 

Historically, announcements from biotech companies have triggered stock price fluctuations as investors misinterpret the details. However, two recent instances suggest this pattern might be shifting.

While 2024 has seen two buyouts of antibody-drug conjugate specialists with $1bn-plus price tags, the focus on ADCs has continued, accounting for almost half of recent oncology deals.

Public Company Edition: OS Therapies launched this year’s smallest initial public offering, to fund its lead program in osteosarcoma. Also, Australian firm Telix, after opting out of a US IPO, grossed A$650m ($425.5m) from investors at home. Day One raised $175m in a private placement.